Small Cell Lung Cancer Management: Emerging Drugs and Promising Strategies

What Is Small Cell Lung Cancer?

Small cell lung cancer is an aggressive form of lung cancer. It shows early metastasis and is reported to be about 15% of all lung cancers. This cancer initially arises from the neuroendocrine (hormone-producing) precursor cells and, with rapid growth, accounts for about 70% of patients with metastasized (rapidly spreading) disease. Small-cell lung cancer responds well to initial treatments but significantly less to second-line therapies. The response rate to second-line chemotherapy is considerably lower than that to first-line agents. There seems to be a high unmet need for treatments to improve the survival rate in patients with small-cell lung cancer.

What Are the Strategies Followed in the Treatment of Small Cell Lung Cancer?

The new strategies for the management of small-cell lung cancer include the consideration of previously treated patients, the use of new agents after receiving the evidence of partial response in an attempt to improve the response, the incorporation of new agents with a combination regimen, and the introduction of new agents in previously untreated patients with extensive small-cell lung cancer.

• Patients with immediate recurrence after the treatment rarely respond to subsequent chemotherapies.

• After 3 months or more, patients with recurrence may show a reasonable response to subsequent chemotherapy.

• Using a new agent as part of the combination is ineffective, as its effect can be masked by the combination.

• The result may show false negatives when new agents are incorporated in partial response cases, due to drug resistance already developed. This method can be applied to the identification of biological agents.

• A higher response rate is observed with testing new agents in previously untreated patients than in previously treated groups. This method helps in the successful identification of Carboplatin, Teniposide, chronic oral Etoposide, and Epirubicin.

• During phase 2 clinical trials, an increased risk of disease-related early death was reported.

A better understanding of the biology of small-cell lung cancer leads to the development of novel therapeutic strategies.

Lurbinectedin:

• Lurbinectedin is a ribonucleic acid (RNA) polymerase 2 inhibitor component that targets active transcription (protein synthesis). This drug blocks protein synthesis in cancer cells.

• It has a direct cytotoxic (cell-killing) effect that induces apoptosis (cell death) in actively dividing tumor cells and also affects tumor-associated macrophages (a type of immune cell).

• A combination of Lurbinectedin and Doxorubicin provides a 92% recovery rate with a progression-free survival of around 6 months.

• Its toxic side effects are observed hematologically, resulting in grade 3 to 4 neutropenia (decreased number of neutrophils) in about 95%, leukopenia (decreased number of white blood cells) in about 79%, anemia in about 47%, and thrombocytopenia (lower levels of platelets) in about 26% of cases.

Aurora-A Kinase Inhibition:

• Aurora-A kinase is involved in mitosis (cell division) and is expressed in small-cell lung cancer.

• Aurora-A kinase binds to c-MYC, a transcription factor observed in 18 to 31% of cases.

• Aurora-A kinase inhibitors initiate apoptosis and present an appealing therapeutic strategy. It blocks cell division and multiplication of cancer cells.

• The adverse effects of the drug were reported hematologically, with 37% of cases having grade III to IV neutropenia, 12% having grade III to IV anemia, 8% having grade III to IV thrombocytopenia, and 5% having grade III to IV fatigue.

Poly-ADP Ribose (PARP) Inhibition:

• The poly-ADP ribose inhibitor acts as an immunomodulator (a modulator of the immune system) in the treatment of small-cell lung cancer.

• The biomarker of poly-ADP ribose inhibitors in small cell lung cancer is the expression of Schlafen-11 (SLFN-11), which stimulates a response to DNA damage and replication stress.

• The expression of Schlafen-11 (SLFN-11) in immunohistochemistry correlates with the randomized phase 2 trials evaluating the combination of Temozolomide plus Veliparib versus Temozolomide plus placebo.

• The combination of Temozolomide plus Veliparib results in significant improvement in Schlafen-11 expression in the majority of patients.

• In patients receiving Temozolomide plus placebo, no difference in progression-free survival or overall survival is observed.

What Are the Novel Formulations of Chemotherapy?

• The cytotoxic agents have limited efficiency in relapsed or recurrent small cell lung cancer, but their use can be limited due to their adverse effects of toxicity.

• New cytotoxic agents and new formulations are emerging in chemotherapy-based approaches. For example, the recent emergence of nanoparticle albumin-bound (nab) Paclitaxel has been introduced as a well-tolerated and effective agent for treating non-small cell lung cancer, breast cancer, and pancreatic cancer.

• Patients are administered nab-Paclitaxel monotherapy on the first, eighth, and 15th days in a 28-day cycle.

• The adverse effects of the drug include grade III to IV neutropenia.

• Irinotecan is a nanoliposomal formulation designed to reduce serum exposure and to deliver the drug through leaky tumor vasculature, where macrophages activate it.

• Nanoliposomal Irinotecan (Nal-IRI) is administered intravenously at a dose of 70 milligrams per square meter every 2 weeks.

• The early efficiency of the drug reports a recovery rate of about 33.3%.

• In patients with platinum-sensitive relapse, retreatment is provided with platinum plus Etoposide, which is considered more effective.

• The emergence of novel strategies to re-sensitize small-cell lung cancer tumors to platinum-based chemotherapy.

• RRX-001 is derived from Dinitroazetidine, which has epigenetic modulation and induction of the M1 macrophage phenotype.

• The reports suggest a median overall survival of 8-12 months and an overall survival rate of 44%.

• In patients with platinum-resistant disease, the recovery rate is about 21%, and the median overall survival duration is about eight months.

• The adverse effects include infusion site reactions (about 23%), headaches (about 11%), and decreased appetite (about 15%).

• Delta-like protein 3 (DLL3) belongs to the member of the NOTCH receptor ligand family that helps in inhibiting NOTCH activation. This type of protein is expressed in about 80% of small-cell lung cancers.

Conclusion:

The development of new drugs and strategies for small-cell lung cancer is remarkably challenging due to its typical patient characteristics, aggressive biology, and various practical challenges. Immunotherapy received new approvals, with the paradigm shift initially in the third-line setting and later in the first-line setting.

The limitations remain in providing the standard therapy for patients who relapse after chemotherapy and immunotherapy. If you want to learn more about the newest treatment options for SCLC, talk to a cancer specialist.

Key Takeaways:

• Small cell lung cancer (SCLC) is a very aggressive type of lung cancer that spreads quickly.

• In addition to traditional platinum-based chemotherapy, doctors are now using immunotherapy drugs, along with therapies that target new cancer pathways.

• First-line treatment for SCLC is platinum-based chemotherapy (Cisplatin or Carboplatin) plus Etoposide.

• For extensive-stage SCLC, immunotherapy (such as Atezolizumab or Durvalumab) is added to chemotherapy.

• If the first treatment doesn’t work, doctors choose the next medicines based on how the cancer reacted before. Common options include Topotecan or Lurbinectedin, with alternatives such as clinical trials, Irinotecan, or platinum re-challenge.